10:17 AM EDT, 07/09/2024 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Tuesday that Peru's General Directorate of Medicines, Supplies and Drugs has approved the oral Orladeyo therapy to prevent hereditary angioedema attacks in patients 12 years and older.

The company said it has an exclusive collaboration with Pint Pharma to register and promote Orladeyo in the pan-Latin America region. Orladeyo was previously approved in Chile, Argentina, Brazil and Mexico, according to the company.

Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling.

Price: 6.41, Change: -0.01, Percent Change: -0.16